What do Spanish registries report about worsening events in chronic heart failure? Needs and challenges

References

• RECALCAR. Resources and quality in cardiology 2021. Available at: https://secardiologia.es/images/institucional/sec-calidad/sec-recalcar/RECALCAR_2021_v2.pdf.
   Google Scholar
• Target 2025. Heart failure. Available at: https://www.semg.es/images/2021/Noticias/objetivo_2025_insf.cardiaca.pdf.
   Google Scholar
• Sicras-Mainar A, Sicras-Navarro A, Palacios B, et al. Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. Rev Esp Cardiol (Engl Ed). 2022;75(1):31–38. doi: 10.1016/j.recesp.2020.09.014
   PubMed Web of Science ®Google Scholar
• Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E, et al. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study Rev Esp Cardiol. 2008;61(10):1041–1049.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009;54(18):1695–1702. doi: 10.1016/j.jacc.2009.08.019
   PubMed Web of Science ®Google Scholar
• Masip J, Frank Peacok W, Arrigo M, et al. Acute heart failure in the 2021 ESC heart failure guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European society of cardiology. Eur Heart J Acute Cardiovasc Care. 2022;11(2):173–185. doi: 10.1093/ehjacc/zuab122
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Senni M, Metra M, et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013;6(3):473–481. doi: 10.1161/CIRCHEARTFAILURE.112.000161
   PubMed Web of Science ®Google Scholar
• Bonilla-Palomas JL, Anguita-Sánchez MP, Elola-Somoza FJ, et al. Thirteen-year trends in hospitalization and outcomes of patients with heart failure in Spain. Eur J Clin Invest. 2021;51(11):e13606. doi: 10.1111/eci.13606
   PubMed Web of Science ®Google Scholar
• Anguita Sánchez M, Bonilla Palomas JL, García Márquez M, et al. Temporal trends in hospitalization and in-hospital mortality rates due to heart failure by age and sex in Spain (2003-2018). Rev Esp Cardiol (Engl Ed). 2021;74(11):993–996.
   PubMed Web of Science ®Google Scholar
• Escobar C, Varela L, Palacios B, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res. 2020;20(1):964. doi: 10.1186/s12913-020-05828-9
   PubMed Web of Science ®Google Scholar
• Eguchi S, Morita Y, Mitani H, et al. Burden of repeated hospitalizations on patients with heart failure: an analysis of administrative and claims data in Japan. Drugs Real World Outcomes. 2022;9(3):377–389. doi: 10.1007/s40801-022-00315-5
   PubMedGoogle Scholar
• Albert NM. An integrative review of the literature on in-hospital worsening heart failure. Heart Lung. 2018;47(5):437–445.
   PubMed Web of Science ®Google Scholar
• Khan MS, Butler J, Greene SJ. Recognizing the significance of outpatient worsening heart failure. J Am Heart Assoc. 2020;9(14):e017485.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Clark AL, Cherif M, McDonagh TA, et al. In-hospital worsening heart failure: a clinically relevant endpoint? ESC Heart Fail. 2018;5(1):9–18.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for the treatment of chronic heart failure. 20 Jul 2017. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf
   Google Scholar
• Arrigo M, Jessup M, Mullens W, et al. Acute Heart Failure. Nat Rev Dis Primers. 2020;6(1):16. DOI:10.1038/s41572-020-0151-7
   PubMed Web of Science ®Google Scholar
• Chung ES, Rickard J, Lu X, et al. Real-world clinical burden among patients with and without heart failure worsening after cardiac resynchronization therapy. Curr Med Res Opin. 2022;38(9):1489–1498. doi: 10.1080/03007995.2022.2092374
   PubMed Web of Science ®Google Scholar
• Gracia E, Singh P, Collins S, et al. The vulnerable phase of heart failure. Am J Ther. 2018;25(4):e456–464.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Fonarow GC, Vaduganathan M, et al. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. 2015;12(4):220–229.
   PubMed Web of Science ®Google Scholar
• Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935–944. doi: 10.1016/j.jacc.2018.11.049
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Butler J. The importance of worsening heart failure: hiding in plain sight. J Am Coll Cardiol. 2022;80(2):123–125.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Butler J, Fonarow GC, et al. Predischarge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018;20(2):281–291. doi: 10.1002/ejhf.1019
   PubMed Web of Science ®Google Scholar
• Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week. J Am Coll Cardiol. 2023;81(4):413–424. doi: 10.1016/j.jacc.2022.11.023
   PubMed Web of Science ®Google Scholar
• Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022;27(2):625–643.
   PubMed Web of Science ®Google Scholar
• Blázquez-Bermejo Z, Farré N, Caravaca Perez P, et al. Dose of furosemide before admission predicts diuretic efficiency and long-term prognosis in acute heart failure. ESC Heart Fail. 2022;9(1):656–666. doi: 10.1002/ehf2.13696
   PubMed Web of Science ®Google Scholar
• Krzesiński P. Digital health technologies for post-discharge care after heart failure hospitalisation to relieve symptoms and improve clinical outcomes. J Clin Med. 2023;12(6):2373.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893. doi: 10.1056/NEJMoa1915928
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105–116. doi: 10.1056/NEJMoa2025797
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. doi: 10.1056/NEJMoa2030183
   PubMed Web of Science ®Google Scholar
• Bakal JA, McAlister FA, Liu W, et al. Heart failure re-admission: measuring the ever shortening gap between repeat heart failure hospitalizations. PLoS ONE. 2014;9(9):e106494.
   PubMed Web of Science ®Google Scholar
• Butler J, Djatche LM, Lautsch D, et al. Representativeness of the VICTORIA trial population in clinical practice: analysis of the PINNACLE registry. J Card Fail. 2021;27(12):1374–1381.
   PubMed Web of Science ®Google Scholar
• Farré N, Vela E, Clèries M, et al. Real world heart failure epidemiology and outcome: a population-based analysis of 88,195 patients. PLoS ONE. 2017;12(2):e0172745.
   PubMed Web of Science ®Google Scholar
• Farré N, Vela E, Clèries M, et al. Medical resource use and expenditure in patients with chronic heart failure: a population-based analysis of 88 195 patients. Eur J Heart Fail. 2016;18(9):1132–1140. doi: 10.1002/ejhf.549
   PubMed Web of Science ®Google Scholar
• Álvarez-García J, Salamanca-Bautista P, Ferrero-Gregori A, et al. Prognostic impact of physician specialty on the prognosis of outpatients with heart failure: propensity matched analysis of the REDINSCOR and RICA registries. Rev Esp Cardiol (Engl Ed). 2017;70(5):347–354. doi: 10.1016/j.recesp.2016.09.021
   PubMed Web of Science ®Google Scholar
• Gómez-Otero I, Ferrero-Gregori A, Varela Román A, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Rev Esp Cardiol (Engl Ed). 2017;70(5):338–346. doi: 10.1016/j.recesp.2016.08.019
   PubMed Web of Science ®Google Scholar
• Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas Ó, et al. Causes of death in hospitalized patients in internal medicine departments with heart failure according to ejection fraction. RICA Registry Med Clin (Barc). 2022;158(1):13–19. doi: 10.1016/j.medcli.2020.10.022
   PubMed Web of Science ®Google Scholar
• González-Guerrero JL, Paredes-Galán E, Ferrero-Martínez AI, et al. Characteristics and one-year outcomes in elderly patients hospitalised with heart failure and preserved, mid-range and reduced ejection fraction]. Rev Esp Geriatr Gerontol. 2020;55(4):195–200. doi: 10.1016/j.regg.2019.12.001
   PubMedGoogle Scholar
• Boureau AS, Annweiler C, Belmin J, et al. Practical management of frailty in older patients with heart failure: statement from a panel of multidisciplinary experts on behalf the heart failure working group of the french society of cardiology and on behalf french society of geriatrics and gerontology. ESC Heart Fail. 2022;9(6):4053–4063. doi: 10.1002/ehf2.14040
   PubMed Web of Science ®Google Scholar
• Martínez Santos P, Bover Freire R, Esteban Fernández A, et al. In-hospital mortality and readmissions for heart failure in Spain. A study of index episodes and 30-day and 1-year cardiac readmissions. Rev Esp Cardiol (Engl Ed). 2019;72(12):998–1004. doi: 10.1016/j.recesp.2019.01.020
   PubMed Web of Science ®Google Scholar
• Lupón J, Bayés-Genís A. Mortality and heart failure hospitalizations. The Need for an exhaustive, official, and standardized registry. Rev Esp Cardiol (Engl Ed). 2019;72(12):988–990.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Parikh RV, Sung SH, et al. Analysis of worsening heart failure events in an integrated health care system. J Am Coll Cardiol. 2022;80(2):111–122. doi: 10.1016/j.jacc.2022.04.045
   PubMed Web of Science ®Google Scholar
• Mallick A, Gandhi PU, Gaggin HK, et al. The importance of worsening heart failure in ambulatory patients: definition, characteristics, and effects of amino-terminal Pro-B-Type natriuretic peptide guided therapy. JACC Heart Fail. 2016;4(9):749–755.
   PubMed Web of Science ®Google Scholar
• Lorenzo M, Palau P, Llàcer P, et al. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure. Eur J Intern Med. 2021;92:94–99.
   PubMed Web of Science ®Google Scholar
• Barge-Caballeroa E, Barge-Caballeroa G, Paniagua-Martína MJ, et al. Prognostic value of a model based on IC-BERG recommendations in ambulatory patients with heart failure. REC CardioClinics. 2022;57(2):76–84.
   Google Scholar
• de Juan Bagudá J, Gavira Gómez JJ, Pachón Iglesias M, et al. Remote heart failure management using the HeartLogic algorithm. RE-HEART registry. Rev Esp Cardiol (Engl Ed). 2022;75(9):709–716. doi: 10.1016/j.rec.2021.09.015
   PubMed Web of Science ®Google Scholar
• Spanish society of cardiology. AVACAR project. Available at: https://secardiologia.es/institucional/reuniones-institucionales/sec-calidad/avacar
   Google Scholar
• Pelat M, Barbe F, Daveu C, et al. SAR340835, a novel selective Na+/Ca2+ exchanger inhibitor, improves cardiac function and restores sympathovagal balance in heart failure. J Pharmacol Exp Ther. 2021;377(2):293–304. doi: 10.1124/jpet.120.000238
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531–1540. doi: 10.1001/jama.287.12.1531
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43. doi: 10.1056/NEJMoa1100171
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Calidd RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–1547. doi: 10.1001/jama.287.12.1541
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland J, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002;360(9328):196–202. doi: 10.1016/S0140-6736(02)09455-2
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen M, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883–1891. doi: 10.1001/jama.297.17.1883
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short- term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103–111.
   PubMed Web of Science ®Google Scholar
• Metra M, Teerlink JR, Cotter G, et al. Effects of serelaxin in patients with acute heart failure. N Engl J Med. 2019;381(8):716–726. doi: 10.1056/NEJMoa1801291
   PubMed Web of Science ®Google Scholar
• Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020;41(25):2379–2392. doi: 10.1093/eurheartj/ehaa183
   PubMed Web of Science ®Google Scholar
• Fudim M, Sayeed S, Xu H, et al. Representativeness of the PIONEER-HF clinical trial population in patients hospitalized with heart failure and reduced ejection fraction. Circ Heart Fail. 2020;13(4):e006645. doi: 10.1161/CIRCHEARTFAILURE.119.006645
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Greene SJ, Zhang S, et al. Applicability of US food and drug administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in US clinical practice: the get with the guidelines-heart failure (GWTG-HF) registry. JAMA Cardiol. 2020;6(3):1–10. doi: 10.1001/jamacardio.2020.5864
   PubMed Web of Science ®Google Scholar
• Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–574. doi: 10.1038/s41591-021-01659-1
   PubMed Web of Science ®Google Scholar
• Qin X, Hung J, Knuiman MW, et al. Evidence-based medication adherence among seniors in the first year after heart failure hospitalisation and subsequent long-term outcomes: a restricted cubic spline analysis of adherence-outcome relationships. Eur J Clin Pharmacol. 2023;79(4):553–567.
   PubMedGoogle Scholar
• Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail. 2011;17(8):664–669.
   PubMed Web of Science ®Google Scholar
• Butler J, Petrie MC, Bains M, et al. Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the post-hospital discharge period. Res Involv Engagem. 2023;9(1):23. doi: 10.1186/s40900-023-00412-x
   PubMedGoogle Scholar
• González-Juanatey JR, Anguita-Sánchez M, Bayes-Genís A, et al. Vericiguat in heart failure: from scientific evidence to clinical practice. Rev Clin Esp (Barc). 2022;222(6):359–369. doi: 10.1016/j.rce.2021.12.005
   PubMed Web of Science ®Google Scholar
• Peschanski N, Harouki N, Soulie M, et al. Transient heart rate reduction improves acute decompensated heart failure-induced left ventricular and coronary dysfunction. ESC Heart Fail. 2021;8(2):1085–1095. doi: 10.1002/ehf2.13094
   PubMed Web of Science ®Google Scholar
• Perera K, Ademi Z, Liew D, et al. Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis. Eur J Prev Cardiol. 2021;28(9):966–972.
   PubMed Web of Science ®Google Scholar
• Hamada T, Kubo T, Kawai K, et al. Frailty in patients with acute decompensated heart failure in a super-aged regional Japanese cohort. ESC Heart Fail. 2021;8(4):2876–2888. doi: 10.1002/ehf2.13363
   PubMed Web of Science ®Google Scholar
• Carballo D, Stirnemann J, Garin N, et al. Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure. ESC Heart Fail. 2020;7(3):1282–1290.
   PubMed Web of Science ®Google Scholar
• Fonarow GC. Improving quality of care and outcomes for heart failure. -Role of registries-. Circ J. 2011;75(8):1783–1790.
   PubMed Web of Science ®Google Scholar
• Lee P, Chin K, Liew D, et al. Economic evaluation of clinical quality registries: a systematic review. BMJ Open. 2019;9(12):e030984.
   PubMed Web of Science ®Google Scholar